Dr. Kornmehl: Thank you all for participating in this discussion about conductive keratoplasty (CK). Ed, what is the mechanism of CK
What ophthalmologists need to know about neuromyelitis optica spectrum disorder
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO
Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention
Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501
Pegcetacoplan injection preserves visual function at 36 weeks in patients with geographic atrophy